Biotechnology

Tuesday Nov 29, 2022 - 1:16 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT), Sensio Group Partner to Distribute 3D Monitoring System – RoomMate(TM)

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today announced its entry into a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing RoomMate(TM). A 3D infrared monitoring system, RoomMate is a simple and effective solution for looking after patients without intruding on their personal space. The solution allows for a…

Tuesday Nov 29, 2022 - 11:47 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “We are excited that the study results confirm the inhalation concept of our exclusively licensed…

Tuesday Nov 29, 2022 - 9:52 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock will trade on the Nasdaq Capital Market on a split-adjusted…

Wednesday Nov 23, 2022 - 2:55 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for Glioblastoma Multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and…

Wednesday Nov 23, 2022 - 10:52 am

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps…

Tuesday Nov 22, 2022 - 9:50 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has closed on a private placement with two healthcare-focused institutional investors. The placement included the sale of 1,818,185 INM common shares, which were issued at a purchase price of $3.30 per share (or prefunded warrant in lieu thereof); the shares were priced at-the-market under NASDAQ rules.…

Monday Nov 21, 2022 - 11:05 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (“RA”), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue,…

Monday Nov 21, 2022 - 10:01 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at the January 2023 Biotech Showcase

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the upcoming Biotech Showcase conference. The event is slated to take place Jan. 9-11, 2023, in San Francisco in parallel to the J.P. Morgan (“JPM”) 41st Annual Health Care Conference. Reichman…

Friday Nov 18, 2022 - 10:31 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has entered into a securities purchase agreement with two healthcare-focused institutional investors. The agreement outlines plans for the issuance and sale of 1,818,185 of INM common shares; the shares will be issued at a purchase price of $3.30 per share or prefunded warrant. In addition, the…

Thursday Nov 17, 2022 - 10:18 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has named Sarah Li as vice president of accounting and InMed controller; the change will be effective Nov. 20, 2022. Li is replacing Brenda Edwards, who has been serving as interim chief financial officer for the company. Edwards joined InMed in the interim contract role in…

Wednesday Nov 16, 2022 - 1:04 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Growing Portfolio with Valuable New Patent

HeartBeam (NASDAQ: BEAT), a cardiac technology company, has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for timely heart attack detection. The company today announced that the United States Patent and Trademark Office has allowed its patent for a 12-lead electrocardiogram (“ECG”) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias. The innovation expands HeartBeam’s growing intellectual property portfolio enabling 12-lead…

Wednesday Nov 16, 2022 - 10:57 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation…

Tuesday Nov 15, 2022 - 12:31 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has scheduled its Annual Meeting of Stockholders; the meeting is slated for Jan. 12, 2023. According to the announcement, any proposals to be considered for the meeting should be sent to the company’s principal executive offices in Las Vegas; all proposals must comply with the…

Tuesday Nov 15, 2022 - 12:13 pm

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases, today announced financial results for the third quarter ended Sept. 30, 2022, and provided a corporate update. “Initial, preliminary data from our second patient dosed with CycloSam continues to show positive signals in terms of safety and efficacy. While it is too early…

Tuesday Nov 15, 2022 - 11:04 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Congratulates Dirk Görlich on $1.4M World Laureates Association Prize in Life Sciences

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today congratulated its co-lead scientific research collaborator Professor Dr. Dirk Görlich, director at the Max Planck Institute for Multidisciplinary Sciences (“MPI”), on being awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine…

Tuesday Nov 15, 2022 - 10:47 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening our drug discovery platform of differentiated preclinical compounds,” said Cybin’s CEO Doug…

Monday Nov 14, 2022 - 3:02 pm

InvestorNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Announces Strategic Move to Sell Alta Mesa Project, Focus on Uranium and Rare Earth Production

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium and rare earth elements (“REE”), today announced its entry into a definitive agreement to sell three wholly owned subsidiaries that together hold its Alta Mesa ISR Project to enCore Energy for total consideration of $120 million (the “transaction”). The transaction, which is expected to close by the end of 2022 or early…

Monday Nov 14, 2022 - 9:53 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has reported its financial results for the first quarter of fiscal year 2023, ended Sept. 30, 2022. Highlights of the report included updates on the company’s pharmaceutical development programs, including INM-755 for the treatment of epidermolysis bullosa (“EB”) and INM-088 for the treatment of glaucoma. According to the report, enrollment and…

Friday Nov 11, 2022 - 10:04 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2022 Financial Report

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its financial and operational updates for the third quarter; the quarter ended on Sept. 30, 2022. Included in the report is the fact that the company’s AIMI(TM) platform technology, which is used for diagnosing heart attacks, has been submitted…

Thursday Nov 10, 2022 - 12:13 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Progress on Clinical Path for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced progress on its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“DMT”). According to the update, dosing has been completed for four out of five participant cohorts, and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The trial was acquired from Entheon Biomedical Corp. in…

Thursday Nov 10, 2022 - 11:48 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that its CEO Eric A. Adams and SVP of Preclinical Research and Development Eric Hsu will present at Tribe Public’s upcoming webinar presentation and Q&A event. Titled “Exploring the Neuroprotective Qualities of Rare Cannabinoids,” the event is scheduled to begin at 8:30 a.m. Pacific…

Monday Nov 07, 2022 - 1:53 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Targeted ‘Finish Line Is Within Sight’ as It Pursues Potential GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) has been developing drug candidates for treating primary and metastatic brain and central nervous system cancer. “Berubicin, the company’s lead drug candidate, is a novel anthracycline in an ongoing international trail in glioblastoma (“GBM”) treatment. The interim analysis data from this potentially pivotal trial is expected in mid-2023… Berubicin was the first [anthracycline] to provide scientific data which appears to demonstrate…

Thursday Nov 03, 2022 - 2:43 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is focused on fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. “Silo Pharma is currently developing ketamine treatments for fibromyalgia – a chronic disease that causes pain throughout the body. With no cure available, fibromyalgia can be a debilitating…

Thursday Nov 03, 2022 - 12:32 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at RAFT 14 Conference

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that its Head of Technical R&D, Dr. Dalit Weinstein Fischer, will attend and present at Recent Advances in Fermentation Technology (“RAFT”) 14. The conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”) is taking place from Nov.…

Thursday Nov 03, 2022 - 11:51 am

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the company’s newest entity. Additions to the executive team include Erik Emerson, named chief commercial officer, and Greg Gironda, named chief operating officer. These two together have…

Thursday Nov 03, 2022 - 10:13 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at 8:00 a.m. GMT on Nov. 15. Drysdale will also participate…

Wednesday Nov 02, 2022 - 12:45 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Selects POD Group’s Advanced Connectivity Solutions for SmartSole(TM) Platform

MetAlert (OTC: MLRT), a pioneer in the field of wearable GPS human and asset tracking and remote patient monitoring, has selected Pod Group’s ENO ONE IoT SIM cards and advanced connectivity solutions for enterprise IoT applications for its award-winning, two-way GPS SmartSole. A wearable medical monitoring device, SmartSole is integrated into an orthotic insole allowing discreet and unobtrusive tracking and remote monitoring of Alzheimer’s, dementia…

Wednesday Nov 02, 2022 - 11:37 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear…

Tuesday Nov 01, 2022 - 12:46 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes…

Tuesday Nov 01, 2022 - 10:34 am

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. “We were very pleased with the functionality and performance of the Nasal Device during the phase I study and its administration of…

Monday Oct 31, 2022 - 1:53 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox…

Monday Oct 31, 2022 - 1:13 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Pleased with Safety Profile of Its PRV-002 Concussion Treatment

Odyssey Health (OTC: ODYY) recently announced the completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial. “Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to determine drug safety. A total of 40 healthy subjects took part in the study. In Cohort I, eight patients received a low dose of the drug, and…

Thursday Oct 27, 2022 - 11:18 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced the graduation of highly skilled facilitators who are now prepared to handle a range of experiences that participants of psychedelic-assisted psychotherapy may undergo. The training program includes foundational training enabling participants to learn the skills necessary to provide ethical care for and…

Wednesday Oct 26, 2022 - 1:36 pm

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Expedite Return to Work, Play Following Concussive Episode

Odyssey Health (OTC: ODYY), a medical company with a focus in the area of life-saving medical solutions, has developed a fully synthetic, non-naturally occurring neurosteroid known as PRV-002 intended to treat concussion or mild traumatic brain injury (“mTBI”). “Designed to be administered within a few minutes of a concussive episode, PRV-002 induces an intracellular steroid receptor in brain cells, with the stimulation of this receptor…

Wednesday Oct 26, 2022 - 11:55 am

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical trial site for its phase 1 CycloSam study. RCINJ has been approved to begin enrolling patients into the study, which will evaluate the effectiveness of CycloSam in treating patients with bone…

Wednesday Oct 26, 2022 - 10:05 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced that it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness Week is Oct. 25-31, 2022. “In severe cases of epidermolysis bullosa, or EB, the very fragile skin tears easily and forms painful blisters and open…

Tuesday Oct 25, 2022 - 11:53 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 2022 Results Conference Call

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced that it will hold a conference call at 4:30 p.m ET on Thursday, Nov. 10, 2022. HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the call, during which time they will…

Monday Oct 24, 2022 - 2:26 pm

InvestorNewsBreaks – Octane’s Upcoming Forum to Showcase Visionary Speakers, Latest Advances in Medical Technology Sector

Octane, an organization leading the Southern California technology and medical technology business ecosystem, today announced that the 2022 Medical Innovation Forum will be held on Oct. 27-28 at the Irvine Marriott in Irvine, California. The two-day event will feature the most visionary speakers from the medical technology sector, showcase the latest advances, and offer access to unparalleled educational opportunities and the potential to network, explore…

Monday Oct 24, 2022 - 1:41 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at LD Micro Main Event XV

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, has announced that its Director of Investor Relations, Joshua Phillipson, will attend and present at the LD Micro Main Event XV. The leading small cap investor conference is taking place in Los Angeles on Oct. 25 to 27, 2022, and…

Monday Oct 24, 2022 - 1:03 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions

Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions